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https://doi.org/10.1016/j.stemcr.2021.02.008SUMMARYCOVID-19 patients often develop severe cardiovascular complications, but it remains unclear if these are caused directly by viral infection
or are secondary to a systemic response. Here, we examine the cardiac tropism of SARS-CoV-2 in human pluripotent stem cell-derived
cardiomyocytes (hPSC-CMs) and smoothmuscle cells (hPSC-SMCs).We find that that SARS-CoV-2 selectively infects hPSC-CMs through
the viral receptor ACE2,whereas in hPSC-SMCs there isminimal viral entry or replication. After entry into cardiomyocytes, SARS-CoV-2 is
assembled in lysosome-like vesicles and egresses via bulk exocytosis. The viral transcripts become a large fraction of cellular mRNAwhile
host gene expression shifts fromoxidative to glycolyticmetabolismandupregulates chromatinmodification andRNA splicing pathways.
Most importantly, viral infection of hPSC-CMs progressively impairs both their electrophysiological and contractile function, and causes
widespread cell death. These data support the hypothesis that COVID-19-related cardiac symptoms can result from a direct cardiotoxic
effect of SARS-CoV-2.INTRODUCTION
With over 100 million people affected worldwide, the
outbreak of severe acute respiratory syndrome coronavirus
2 (SARS-CoV-2) has already left its permanent mark on hu-
man history (Hopkins, 2020; Zhu et al., 2020). SARS-CoV-2
belongs to the family of Coronaviridae, a large group of sin-
gle-stranded enveloped RNA viruses reported for the first
time in humans in the 1960s (Andersen et al., 2020; Cor-
man et al., 2018; Cui et al., 2019). Besides being long recog-
nized as one of the common cold viruses, coronaviruses
took center stage in infectious disease medicine following
the outbreaks of SARS-CoV in 2003 and of Middle East res-
piratory syndrome coronavirus (MERS-CoV) a decade later.
Coronaviruses became thus recognized as highly patho-
genic for humans, with a symptomatology that focuses
on the respiratory system while often also involving ex-
tra-respiratory organs (Alhogbani, 2016; Nishiga et al.,
2020; Oudit et al., 2009; Zhou et al., 2020). Indeed, even
though the lungs represent the main target, cardiovascular
complications (including worsening of pre-existing condi-
tions and onset of new disorders) were not only reported478 Stem Cell Reports j Vol. 16 j 478–492 j March 9, 2021 j ª 2021 The Aut
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contributing to the mortality of COVID-19 patients during
the ongoing pandemic (Alhogbani, 2016; Oudit et al.,
2009; Shi et al., 2020; Zhou et al., 2020).
The most common cardiovascular complications
observed after SARS-CoV-2 infection are myocardial injury
(including cases with and without classic coronary occlu-
sion), arrhythmias, and heart failure (Baggiano et al.,
2020; Nishiga et al., 2020; Ojha et al., 2020; Ruan et al.,
2020; Shi et al., 2020; Wang et al., 2020; Xu et al., 2020;
Zhou et al., 2020). In particular, myocardial injury, charac-
terized by elevated serum levels of cardiac troponin I and/
or electrocardiogram abnormalities, has been indepen-
dently associated with increased mortality in COVID-19
patients (Guo et al., 2020). Moreover, as reported also for
SARS-CoV (Madjid et al., 2007), SARS-CoV-2 can trigger
acute coronary syndrome even in the absence of systemic
inflammation (Nishiga et al., 2020; Wang et al., 2020).
Retrospective studies show that hospitalized COVID-19 pa-
tients develop cardiac arrhythmias, including ventricular
tachycardia and atrial fibrillation (Bhatla et al., 2020; Ma-
laty et al., 2020; Wang et al., 2020; Zylla et al., 2021).hors.
ns.org/licenses/by/4.0/).
Progressive left ventricular dysfunction and overall symp-
toms that resemble heart failure have also been observed
in a significant number of patients (Dong et al., 2020;
Huang et al., 2020a; Wang et al., 2020; Zhou et al., 2020).
At the beginning of the outbreak, this symptomatology
was reported mostly in critically ill COVID-19 patients
(Zhou et al., 2020). A sizable number ofmore recent studies
has reported that cardiac symptoms are observed also in
mild and even asymptomatic cases of COVID-19 (Arentz
et al., 2020; Huang et al., 2020b; Inciardi et al., 2020; Punt-
mann et al., 2020; Rajpal et al., 2021).
The mechanisms behind cardiac disease reported for
COVID-19 are still unclear (Nishiga et al., 2020; Zhou
et al., 2020). Upon lung infection, the uncontrolled release
of inflammatory cytokines, termed ‘‘cytokine storm,’’
could inducemulti-organ damage, ultimately leading to or-
gan failure and worsening of pre-existing cardiovascular
disorders (Driggin et al., 2020; Inciardi et al., 2020; Tay
et al., 2020).Moreover, COVID-19 is associatedwith coagu-
lopathies, which also can induce ischemic heart damage
(Driggin et al., 2020; Nishiga et al., 2020; Ranucci et al.,
2020). Finally, SARS-CoV-2 could directly mediate heart
injury by entering cardiomyocytes or other cardiac stromal
and/or vascular cells via binding of the viral spike glycopro-
tein to its extracellular receptor, angiotensin I converting
enzyme 2 (ACE2) (Baggiano et al., 2020; Hoffmann et al.,
2020). This protein is expressed in different tissues of the
human body, including cardiomyocytes and cardiac peri-
cytes, and its primary function is to counterbalance the
renin-angiotensin-aldosterone system (Chen et al., 2020a;
Hikmet et al., 2020; Li et al., 2020; Verdecchia et al., 2020).
Several studies detected SARS-CoV-2 genome in the heart
and/or reported signs of viral myocarditis in COVID-19-in-
fected individuals, including asymptomatic cases (Bradley
et al., 2020; Dolhnikoff et al., 2020; Lindner et al., 2020;
Rajpal et al., 2021).Moreover, in vivo and in vitro studies uti-
lizing both human adult cardiomyocytes and human
pluripotent stem cell-derived cardiomyocytes (hPSC-CMs)
have shown that SARS-CoV-2 can infect cardiomyocytes,
indicating that SARS-CoV-2 could exhibit cardiac tropism
(Bojkova et al., 2020; Chen et al., 2020b; Sharma et al.,
2020; Yang et al., 2020). However, whether SARS-CoV-2
infection of human cardiomyocytes leads to a direct
impairment of cardiac function is still unresolved. Further-
more, whether other cardiac cell types are also susceptible
to SARS-CoV-2 remains unclear.
In this study we examine the mechanisms behind
COVID-19-related cardiac symptoms using hPSC-CMs
and hPSC-derived smooth muscle cells (hPSC-SMCs), es-
tablished models for cardiovascular disease research (Ber-
tero et al., 2019b; Cheung et al., 2012; Serrano et al.,
2019; Yang et al., 2018). SARS-CoV-2 specifically infects
and propagates within hPSC-CMs, a process that appearsto exquisitely rely on ACE2 and to both involve direct
membrane fusion and entry through the endo-lysosomal
pathway. Pathways involved in RNA splicing and chro-
matin accessibility are significantly upregulated after infec-
tion, whereas pathways involved in oxidative metabolism
and mitochondrial function are downregulated. SARS-
CoV-2 infection results in disruption of the contractile
cytoskeleton, electrical and mechanical dysfunction, and
eventual cell death. These findings provide evidence for a
direct viral cytopathic pathway involving cardiacmyocytes
in the context of COVID-19-related cardiac disease.RESULTS
hPSC-CMs Express SARS-CoV-2 Receptors and Entry
Cofactors
Susceptibility to SARS-CoV-2 infection is thought to
depend on expression of both the viral receptor ACE2
and various host proteases (Hoffmann et al., 2020; Millet
and Whittaker, 2015; Shang et al., 2020; Zumla et al.,
2016). We found that ACE2 is transcriptionally activated
during cardiac differentiation of both RUES2 embryonic
stem cell-derived cardiomyocytes (hESC-CMs; Figure 1A)
andWTC11c-induced pluripotent stem cell-derived cardio-
myocytes (hiPSC-CMs; Figure S1A). Single-cell RNA
sequencing (RNA-seq) analysis detected ACE2 mRNA in
9% of hESC-CMs, indicating low and/or transitory
expression (Figure 1B). A larger fraction of cells expressed
moderate to high levels of endosomal cysteine proteases
CTSB (cathepsin B; 71.0%) and CTSL (cathepsin L;
46.0%). Detection of these factors is relevant because
they can cleave the spike glycoprotein leading to endo-
membrane fusion-mediated release of the SARS-CoV-2
genome inside the cytoplasm (Kang et al., 2020; Millet
and Whittaker, 2015; Ou et al., 2020; Yang and Shen,
2020). Importantly, these viral processing factors were
often co-expressed with ACE2 (Figure S1B). Although viral
entry can also be mediated by TMPRSS2 (Hoffmann et al.,
2020; Shulla et al., 2011), this transmembrane serine prote-
ase was not detectable in hESC-CMs (Figure S1C), as also re-
ported for the adult humanheart (Litvinukova et al., 2020).
Interestingly, the lipid phosphatase, PIKFYVE, another en-
dosomal viral processing factor, and FURIN, a membrane-
bound serine protease, were also broadly expressed in
hESC-CMs (Figure S1C), overall suggesting that the mech-
anism of SARS-CoV-2 entry in cardiomyocytes might be
different from the TMPRSS2-dependent one reported for
lung epithelial cells (Hoffmann et al., 2020; Schneider
et al., 2020; Shang et al., 2020; Xia et al., 2020b).
Despite the relatively low levels of mRNA, ACE2 protein
was clearly detectable bywestern blot in hPSC-CMs derived
from multiple lines (RUES2 female hESCs, H7 femaleStem Cell Reports j Vol. 16 j 478–492 j March 9, 2021 479
Figure 1. hPSC-CMs Express SARS-CoV-2 Receptors and Processing Factors
(A) RNA-seq during RUES2 hESC-CM differentiation. ACE2 is quantified as fragments per kilobase of transcript per million mapped reads
(FPKM). Mean ± SEM of two independent experiments. ESC, embryonic stem cells (day 0); ME, mesoderm (day 2); CP, cardiac progenitors
(day 5); CM, cardiomyocytes (day 14).
(B) Single-cell RNA-seq gene expression heatmaps from RUES2 hESC-CMs after dimensionality reduction through Uniform Manifold
Approximation and Projection (UMAP). TNNT2 provides a pan-cardiomyocyte marker.
(C) Western blot for ACE2 in hPSC-CMs from multiple lines and different types of hPSC-SMCs. LM, lateral plate mesoderm-derived; NC, neural
crest-derived; hPSCs, negative control; VERO cells, positive control.
(D) Quantification of ACE2 level normalized by GADPH. Mean ± SEM of three independent experiments.hESCs, and WTC11c male hiPSCs), reaching levels compa-
rable with those of VERO cells, a primate kidney epithelial
line with established SARS-CoV-2 tropism (Figures 1C and
1D). Emphasizing the specific tropism of SARS-CoV-2 for
hPSC-CMs, ACE2 was expressed at very low levels in
hESC-SMCs of varying embryonic origin (lateral meso-
derm- or neural crest-derived, all differentiated from H9 fe-
male hESCs; Figures 1C and S1D). Collectively, hPSC-CMs
express proteins that may render them susceptible to
SARS-CoV-2 infection (Bojkova et al., 2020; Sharma et al.,
2020; Yang et al., 2020).
SARS-CoV-2 Can Infect and Replicate in hPSC-CMs
Using ACE2
Since H7- and WTC11c-derived hPSC-CMs showed the
highest levels of ACE2 (Figures 1C and 1D), we tested their
functional susceptibility to SARS-CoV-2. For this, we incu-
bated highly pure hPSC-CMs (over 80% positive for cardiac
troponin T [cTnT+]; Figure S2A) with SARS-CoV-2/Wa-1
strain. We used a multiplicity of infection (MOI) (i.e., the
number of infectious viral particles per cell) of either 0.1
(requiring propagation of the virus within the cells and sec-
ondary infection of others) or 5 (aiming to infect all suscep-
tible cells at the same time). We observed marked and480 Stem Cell Reports j Vol. 16 j 478–492 j March 9, 2021disseminated viral cytopathic effects in both H7 hESC-
CMs and WTC11c hiPSC-CMs. These effects were acceler-
ated at 5 MOI, as expected (Figures 2A and S2B). Most
notably, the highest MOI led to cessation of beating and
signs of cell death as early as at 48 h post infection (hpi)
in both cell lines, withmore pronounced effects for H7 car-
diomyocytes. Immunofluorescence staining of SARS-CoV-
2 nucleocapsid protein revealed substantial presence of
viral factors in the cytoplasm of both H7 hESC-CMs and
WTC11c hiPSC-CMs (Figures 2B and S2C).
To investigate whether hPSC-CMs are permissive to
SARS-CoV-2 replication, we quantified extracellular viral
particles and intracellular viral RNA (by plaque assay
and quantitative reverse transcription PCR [qRT-PCR],
respectively). The one-step growth curve after 5 MOI
infection indicated that viral replication occurred steadily
from 24 to 72 hpi, followed by a precipitous decline as the
cells died (Figure 2C). The multi-step growth curve (0.1
MOI infection) confirmed that SARS-CoV-2 replicated in-
side hPSC-CMs (Figure 2D), with a marked increase in
viral particles and RNA at 48 and 72 hpi (at which point
the experiment was stopped). In agreement with morpho-
logical observations, H7-derived cardiomyocytes were
more permissive to SARS-CoV-2 replication than
Figure 2. hPSC-CMs Are Permissive to SARS-CoV-2 Infection and Replication
(A) Cytopathic effects of SARS-CoV-2 at 5 MOI in H7 hESC-CMs and WTC11c hiPSC-CMs during a time course of 120 h. Scale bars, 100 mm.
(B) Immunofluorescent staining of H7 hESC-CMs and WTC11c hiPSC-CMs at 48 hpi with SARS-CoV-2 dose of 0.1 MOI. Scale bars, 50 mm.
Individual channels are shown in Figure S2C.
(C) One-step viral growth curve in H7 hESC-CMs infected with SARS-CoV-2 at 5 MOI over a time course of 120 h.
(D) Multi-step viral growth curve in H7 hESC-CMs infected with SARS-CoV-2 at 0.1 MOI over a time course of 72 h. For both (C) and (D), lines
connect the means of two independent experiments. Viral RNA indicating intracellular viral replication is plotted on the left y axis as
percent of HPRT1. Viral particles secreted in the supernatant are plotted on the right y axis as plaque-forming units (PFU) per mL.
(E) Cytopathic effects of 0.1 MOI and 5 MOI of SARS-CoV-2 at 72 hpi in wild-type (WT) and ACE2 knockout (KO) WTC11c-CMs. Two ACE2 KO
hiPSC clones (cl.1 and cl. 2) were analyzed (Figure S3). Scale bars, 100 mm.
(F) Fluorescence microscopy assessment of viral entry of icSARS-CoV2-mNG at 0.1 MOI in WTC11c-CMs WT and ACE2 KO clones at 48 and
72 hpi. mNG fluorescence is shown in grayscale. ACE2 KO clones showed background autofluorescence only. Scale bars, 100 mm.WTC11c-derived ones (compare Figures 2C, 2D, S2D, and
S2E), perhaps as a reflection of genetic or epigenetic differ-
ences that deserve further study.Distinct from hPSC-CMs, hESC-SMCs exposed to SARS-
CoV-2didnot showany cytopathic effects even at thehigh-
est MOI at 72 hpi (Figure S2F). Accordingly, extracellularStem Cell Reports j Vol. 16 j 478–492 j March 9, 2021 481
viral particles and intracellular viral RNA in hPSC-SMCs
were more than two orders of magnitude lower than the
ones observed for hPSC-CMs (Figure S2G). These findings
highlight the specific tropism of SARS-CoV-2 for hPSC-
CMs, and exclude that cytopathic effects observed in cardi-
omyocytesmaybeattributable to toxic contaminants in the
viral preparation.
To investigate the role of ACE2 during cardiomyocyte
infection by SARS-CoV-2, we generated ACE2 knockout
(KO) WTC11c hiPSC-CMs (Figures 3A–3D). Loss of ACE2
prevented cell death following SARS-CoV-2 exposure
even at 5 MOI (Figure 2E). To confirm the absence of viral
entry inACE2KO cells, we used SARS-CoV-2 genetically en-
gineered to express the mNeonGreen protein (mNG) (Xie
et al., 2020). Similarly to wild-type SARS-CoV-2, the SARS-
CoV-2-mNG reporter became detectable at 48 hpi at 0.1
MOI only in wild-type cardiomyocytes, with increased
fluorescence intensity at 72 hpi (Figure 2F). Overall, these
findings indicate that SARS-CoV-2 infection in cardiomyo-
cytes is prominently mediated by the expression of ACE2.
SARS-CoV-2 Viral Entry, Replication, and Egress
Engage Lysosome-like Structures
To examine in finer detail the viral propagation mecha-
nisms in hPSC-CMs we performed extensive electron mi-
croscopy analyses. We readily identified numerous viral
particles entering and replicating inside the cytoplasm of
WTC11c hiPSC-CMs (Figures 3A and 3B), clearly visible
as 80–90-nm-wide spherical structures, confirming that
hPSC-CMs can be infected directly by SARS-CoV-2. The
presence of viruses was remarkably greater at 72 hpi. Inter-
estingly, we observed both endocytosis of intact virions
(Figure 3A) and direct fusion of viral envelope with cell
membrane (Figure 3B), suggesting dual mechanisms of en-
try in cardiomyocytes. Double-membrane vesicles, organ-
elles associated with viral replication and assembly, were
commonly seen in close association with viral particles
(Figure 3C) (Snijder et al., 2020). We also observed dilated
membrane-bound tubular structures, likely representing
the endoplasmic reticulum Golgi intermediate compart-
ment, in close proximity tomembrane-enclosed viral parti-
cles (Figure 3D). In addition, we observed a variety of
vesicles containing viruses (Figures 3D–3F). Most notable
were large vesicles with electron dense content packed
with mature virus particles (Figure 3E). In some of these
vesicles, we also observed lipid droplets and multilamellar
bodies, consistent with lysosomes, whereas others were
smooth-walled vesicles (Figures 3E and 3F) (Ghosh et al.,
2020; Snijder et al., 2020). Finally, exocytosis of virions
was readily identifiable on the cell surface (Figures 3G–
3I). In summary, these electron microscopic studies
demonstrated viral entry via both direct fusion and endo-
cytosis, replication in subcellular membrane structures,482 Stem Cell Reports j Vol. 16 j 478–492 j March 9, 2021and ‘‘hijacking’’ of lysosomal vesicles for the bulk release
of mature virions by exocytosis.
SARS-CoV-2 Reprograms Chromatin-Modifying, RNA
Processing, and Energy Metabolism Pathways
To clarify the genome-wide transcriptional alterations
induced by SARS-CoV-2 infection in hPSC-CMs, we per-
formed RNA-seq analyses in both H7 hESC-CMs and
WTC11c hiPSC-CMs subjected to infection at 0.1 or 5
MOI and sampled every 24 h for 3 days. A high fraction of
next-generation sequencing reads mapped to the SARS-
CoV-2 genome at highMOI and/or late time points, partic-
ularly for H7 hESC-CMs (up to 18% of all reads), in
agreement with their stronger susceptibility to SARS-CoV-
2 infection (Figure 4A). Dimensionality reduction of the
data with principal-component analysis (PCA) showed
that gene expression variability correlated most strongly
with the cell type of origin (PC1) and subsequently with
the degree and progression of SARS-CoV-2 infection (PC2)
(Figure 4B). Accordingly, gene expression profiles change
in a time- and dose-dependent manner for both H7-CMs
and WTC11c-CMs, with major differences observed at the
latest time point and with the highest MOI (Figures 4C
and 4D). Interestingly, pathways involved in RNA process-
ing and chromatin accessibility (i.e., histone modification)
were upregulated together with the response to viral infec-
tion, suggesting that SARS-CoV-2 may induce broad
epigenetic reprogramming of the host to promote its own
replication (Figures 4E and S4A; Tables S1 and S3) (Banerjee
et al., 2020). In addition,weobserved that genes involved in
mitochondrial function andenergyproductionwere down-
regulated (Figures 4F and S4B; Tables S2 and S4), indicating
that SARS-CoV-2 might promote a shift toward a glycolytic
metabolism by suppressing mitochondrial oxidative phos-
phorylation, which could also favor its replication (Ajaz
et al., 2021; Icard et al., 2021).
Upon viral infection, pathogen-associatedmolecular pat-
terns (PAMPs) initiate the early immune response via host
pattern recognition receptors. After virus uncoating, RIG-
I-like receptors bind to the uncapped and double-stranded
viral RNA in the cytosol and trigger innate immune activa-
tion, leading to the production of type I and type III inter-
ferons and the interferon-induced antiviral response (Loo
and Gale, 2011). Upregulated pathways after SARS-CoV-2
infection in hPSC-CMs included those involved in viral de-
fense (Figure 4E). To more finely clarify the underlying ki-
netics, we analyzed the interferon response from 2 to
72 hpi by qRT-PCR. We found that interferon transcripts
(INFB1 and IFNL1) were markedly upregulated at 48 and
72 hpi in both cell lines, with a stronger effect in the
more sensitive H7 cardiomyocytes (Figures 4G and S4C).
The interferon-stimulated genes IFIT1 and IFITM1 were
also upregulated at the latest time point. These results
Figure 3. Electron Microscopy Analysis of Infected hPSC-CMs
(A) SARS-CoV-2 enters WTC11c-CMs by endocytosis (white arrow). The dashed box (magnified in the inset) shows a virus in an endosome.
Note that two lipid layers are identifiable. The outer layer (red arrowhead) belongs to the endosome and the inner layer (yellow arrowhead)
to the virus.
(B) A virion envelope fuses directly with the cell membrane upon entry (dashed box and magnified view in the inset).
(C) A double-membrane vesicle (DMV) (dashed box and magnified in the inset) adjacent to two completely formed virus particles inside a
vesicle (arrows).
(D–F) Numerous intracellular virus particles packed into different types of vesicles. White arrows in (D) show smooth-walled vesicles, and
red arrowheads show vesicles with branched connections, most consistent with the endoplasmic reticulum Golgi intermediate
compartment. White arrows in (E and F) show vesicles with viral particles and electron dense content, likely representing lysosomes.
(legend continued on next page)
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indicate that SARS-CoV-2 induces innate immune activa-
tion and interferon response in hPSC-CMs, similar to other
cell types (Lei et al., 2020).
Electrophysiological Characteristics of hPSC-CMs
Infected with SARS-CoV-2
We next investigated whether SARS-CoV-2 infection im-
pairs the function of hPSC-CMs. First, we evaluated electro-
physiological properties of infected H7 hESC-CMs and
WTC11c hiPSC-CMs using multi-electrode arrays (MEA)
over a time course of 72 hpi at MOI of 0.1 and 5. Distinct
from our earlier experiments on sparser hPSC-CM cultures
in standard tissue culture dishes, in this context we did not
observe profound cytopathic effects in any of the condi-
tions (Figures 5A and S5A). This outcome may reflect a
decreased efficiency of viral propagation as hPSC-CMs
were plated at high density to ensure robust assessment
of electrophysiological properties. Nevertheless, viral RNA
and viral particles could still be detected at 0.1 MOI, with
the highest levels at 5 MOI (Figures 5B and S5B), showing
that the infection occurred also in these highly dense
cultures. Representative propagation maps are shown in
Figures 5C and S5C, while representative field potential re-
cordings showcasing changes in spike amplitude and fre-
quency are included in Figures 5D and S5D. Remarkably,
SARS-CoV-2 infection rapidly resulted in reduced beating
rate, lower depolarization spike amplitude, and decreased
electrical conduction velocity (Figures 5E, S5E, and S5F).
In H7 hESC-CMs we also observed a time-dependent in-
crease in the field potential duration (FPD) both in sponta-
neously beating and electrically paced cultures (Figure 5F;
similar measurements could not be reliably obtained
from WTC11c hiPSC-CMs due to the limited amplitude
of the repolarization wave after SARS-CoV-2 infection).
Overall, abnormalities in the generation and propagation
of electrical signals were significant even in the absence
of extensive cell death, suggesting that SARS-CoV-2 infec-
tion in cardiomyocytes could directly create a substrate
for arrhythmias (Bhatla et al., 2020; Zylla et al., 2021).
SARS-CoV-2 Infection Progressively Impairs Force
Generation in Engineered Heart Tissues
We then evaluated the contractile properties of hPSC-CMs
using three-dimensional engineered heart tissues (3D-
EHTs), following their contractile behavior through mag-
netic field sensing (Bielawski et al., 2016) (Figures 6A and
6B). For these experiments we focused on WTC11c hiPSCs
since 3D-EHTs from H7 hESC-CMs proved to beat sponta-
neously at too high a frequency (>2 Hz) to enable accurate(G–I) Virions egressing the cell. Dashed boxes in (G) are magnified in (H
white arrows show vesicles opening into the extracellular space (exo
484 Stem Cell Reports j Vol. 16 j 478–492 j March 9, 2021measurements of contractile behavior (i.e., the tissue had a
tetanic-like contraction with minimal relaxation between
beats at this frequency). We infected 3D-EHTs from
WTC11c hiPSC-CMs with 10 MOI (to facilitate infection
within the non-vascularized, cell-dense tissue), and
analyzed their contraction for a week. This 3Dmodel expe-
rienced viral replication comparable with that of 2D cul-
tures, highlighting once again the cardiac tropism of
SARS-CoV-2 (Figure 6C). The maximal twitch force in in-
fected tissues decreased as early as 72 hpi (Figure S6A),
and the contractions continued to subside to less than
25% of the force measured at the baseline at 144 hpi (Fig-
ures 6D and 6E; Videos S1 and S2). Cardiomyocyte density
progressively decreased while cells also became more
rounded (i.e., dedifferentiated) and less aligned with the
longitudinal axis of the 3D-EHTs (Figures 6F and S6B).
This could collectively contribute to the loss of force pro-
duction. Infected 3D-EHTs also showed decreased expres-
sion of the sarcomeric genes MYL2 and MYH6, which
may be correlated to the loss of sarcomere organization
(Figure 6G). Overall, the significant impairment in the con-
tractile properties of 3D-EHTs demonstrates that the me-
chanical function of cardiomyocytes is impacted by
SARS-CoV-2 infection in vitro, and suggest that similar
mechanisms could contribute to whole-organ cardiac
dysfunction also in patients (Dong et al., 2020).DISCUSSION
A rapidly increasing number of reports acknowledge car-
diovascular involvement as a prevalent complication
observed in COVID-19 patients, but discriminating be-
tween direct versus indirect effects is still an open challenge
(Nishiga et al., 2020; Shi et al., 2020; Tay et al., 2020). In
this study, we show that SARS-CoV-2 has the ability to
directly infect cardiomyocytes, to impair both their electro-
physiological and contractile properties, and to eventually
induce cell death.
In agreement with earlier reports, we find that cardio-
myocytes (but not smooth muscle cells) express ACE2,
making them susceptible to SARS-CoV-2 infection. Our ex-
periments in ACE2 KO hPSC-CMs formally demonstrate
the key role of this factor for SARS-CoV-2 entry in this
cell type. Interestingly, mRNA levels of ACE2 are heteroge-
neous within hPSC-CMs from the same culture, and the re-
sulting protein is differentially abundant in hPSC-CMs
from different genetic backgrounds. The cytopathic effects
of SARS-CoV-2 infection also strongly vary betweenand I). The asterisks in (H and I) show smooth-walled vesicles. The
cytosis), releasing their virions. Scale bars, 100 mm.
Figure 4. Gene Expression Analysis in hPSC-CMs Infected
with SARS-CoV-2
(A) Percentage of RNA-seq reads mapping to the SARS-CoV-2
genome in hPSC-CMs infected with 0.1 or 5 MOI SARS-CoV-2 at
different time points (three technical replicates per condi-
tion).
(B) Principal-component analysis (PCA) plot describing the
gene expression variation between samples. Circles and tri-
angles identify H7-CMs and WTC11c-CMs, respectively. The
outline of empty symbols (uninfected samples) are color-
matched to filled symbols (infected samples) by time point
and MOI.
(C and D) Heatmaps showing significant differentially ex-
pressed genes for infected samples versus mock in H7-CMs (C)
and WTC11c-CMs (D).
(E) Gene ontology (GO) analysis of upregulated pathways in
H7-CMs infected with 5 MOI at 48 hpi.
(F) GO analysis of downregulated pathways in H7-CMs in-
fected with 5 MOI at 48 hpi.
(G) qRT-PCR of interferon response genes in H7 hESC-CMs
infected with SARS-CoV-2 at 0.1 MOI. Mean ± SEM of two
independent experiments.
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Figure 5. Electrophysiological Alterations in hPSC-CMs Infected with SARS-CoV-2
(A and B) (A) Representative images of SARS-CoV-2-infected H7 hESC-CMs on MEA wells at 72 hpi. Scale bars, 50 mm. (B) Intracellular and
extracellular viral particles in H7 hESC-CMs seeded and infected in the MEA plate. Intracellular viral particles are plotted on the right axis as
viral RNA (percent of HPRT1); extracellular viral particles are plotted on the left axis as PFU/mL. Data are shown as mean ± SEM of eight
wells. Differences versus mock control by two-way ANOVA with Sidak correction for multiple comparisons (*p < 0.05, ***p < 0.001).
(C) Representative propagation maps at 72 hpi. The axes illustrate the position of 16 total electrodes, with black dots indicating inactive
ones. Electrical propagation starts in the blue area and moves toward the red area, according to the color-coded time interval.
(D) Representative recordings of spontaneous electrical activity of SARS-CoV-2-infected H7 hESC-CMs at 72 hpi.
(E and F) (E) Representative quantifications of electrophysiological properties from MEA analyses in SARS-CoV-2-infected H7 hESC-CMs.
Mean ± SEM of eight wells. Statistical analyses of intra-experimental variability as for (B). (F) Representative field potential traces in
SARS-CoV-2-infected H7 hESC-CMs at 72 hpi, and quantification of FPD corrected by beat rate in spontaneous and paced experiments. Mean
(legend continued on next page)
486 Stem Cell Reports j Vol. 16 j 478–492 j March 9, 2021
cardiomyocytes derived from different hPSC lines. ACE2
expression and SARS-CoV-2 susceptibility may be similarly
heterogeneous in vivo, both across different regions of the
heart and within different subjects (Litvinukova et al.,
2020). This might partially explain the discrepancy be-
tween the strong prevalence of heart damage in COVID-
19 patients and the limited evidence for viral particles in
the heart found by autopsy examinations. We suggest
that future analyses should aim to sample various regions
of the heart and focus on those patients that had shown
the strongest cardiac symptoms.
A puzzling observation is that the cytopathic effects of
SARS-CoV-2 infectionexpands tovirtually the entiremono-
layer of hPSC-CMs, even though single-cell RNA-seq indi-
cates that many cardiomyocytes do not express detectable
levels of ACE2. One possible explanation is that ACE2 tran-
scription is episodic and/or still meaningful low levels that
are below the sensitivity of single-cell RNA-seq (either way
resulting in sufficient protein levels to allow SARS-CoV-2
entry). Alternatively, cytotoxic stimuli triggered by SARS-
CoV-2 might spread to the adjacent cells via gap junctions
or through the supernatant as toxic cytokines and/or other
danger signals. Finally, the fusogenicproperties of the SARS-
CoV-2 spike protein may mediate membrane fusion not
onlybetweenviral andhostmembranes but alsowithin car-
diomyocytes, leading to intercellular viral spreading
(Schneider et al., 2020). Spike protein fusogenicity is sec-
ondary to its proteolytic cleavage by host proteases, such
as furin (Millet and Whittaker, 2015), which is expressed
in hPSC-CMs. Noticeably, we observed direct fusion be-
tween the virus andhPSC-CMs, a process thatmay bemedi-
ated by proteolytically primed spike proteins, as in the case
ofMERS-CoV (Millet andWhittaker, 2014; Xia et al., 2020a,
2020b). Future studies are needed to clarify whether any of
these non-mutually exclusive mechanisms are involved in
the strong susceptibility of hPSC-CMs to SARS-CoV-2 infec-
tion, and whether similar events are recapitulated in vivo.
We found that hPSC-CMs are also extremely permissive
to viral replication. Among other types of ultrastructural
features, we detected the presence of double-membrane
vesicles. These are used by viruses both to concentrate their
buildingmaterials for efficient replication, and to evade the
immune surveillance by ‘‘hiding’’ viral factors that can
trigger the PAMP pathway (Wolff et al., 2020). Accordingly,
we observed activation of interferon-responsive genes only
at late time points of SARS-CoV-2 infection. The interferon
response, which is part of the innate immune response acti-
vation (Loo and Gale, 2011), usually occurs within hours
from viral infection. The fact that cardiomyocytes infected± SEM of eight and six wells for spontaneously beating and paced cell
as for (B) (**p < 0.01).with SARS-CoV-2 show a delayed response may facilitate
viral replication to high levels (Lei et al., 2020). Further-
more, RNA-seq showed that SARS-CoV-2 infection affects
pathways involved in RNA regulation. SARS-CoV-2 can
impair RNA splicing to evade the intracellular innate im-
mune response (Banerjee et al., 2020), which may be the
case also in hPSC-CMs. Moreover, oxidative phosphoryla-
tion and mitochondrial function are severely downregu-
lated in the infected cells. SARS-CoV-2 may shift cellular
metabolism to promote glycolytic metabolic activity in
support of viral replication (Icard et al., 2021), providing
yet another way to boost its replication also in hPSC-CMs.
The presence of highly replicating virus severely affects
both the morphology and the function of hPSC-CMs. In-
fected cardiomyocytes lose cytoskeletal organization,
become packed with different types of vesicles, and show
broad alterations of gene expression. Using anMEA system,
which has been validated to detect potential arrhythmo-
genicpropertiesofnoveldrugs (Blinovaetal., 2018),we iden-
tified several electrophysiological abnormalities induced by
SARS-CoV-2 infection. Prolongation of FPD is particularly
noticeable. This measurement reflects the interval between
membrane depolarization and repolarization, and as such
represents an in vitro surrogate of the QT interval measured
by an electrocardiogram. It is well known that prolongation
of the QT interval is pro-arrhythmogenic (Chiang and Ro-
den, 2000). Thus, FPD prolongation in SARS-CoV-2-infected
hPSC-CMsmay be an in vitro surrogate phenotypemirroring
the arrhythmias observed in 20% of COVID-19 patients
(Malaty et al., 2020). Last, but not least, we found marked
impairment in both contractile function andhistological or-
ganization in 3D-EHTs infected with SARS-CoV-2. If similar
effects were to occur in the hearts of some COVID-19 pa-
tients, this could contribute to cardiac dysfunction. Overall,
hPSC-CMs on MEAs and/or organized in 3D-EHTs may
represent valuable scalable platforms to identify active com-
pounds that may provide therapeutic value.
Collectively, our results support thenotion that, indepen-
dent of inflammation or coagulopathy, SARS-CoV-2 can
cause direct functional heart damage by either inducing
cell death and/or by impairing electro-mechanical func-
tions. One limitation of this study is our reliance on
hPSC-CMs, which are well known for their functional
immaturity (Guo andPu, 2020; Karbassi et al., 2020;March-
iano et al., 2019). While the in vitro systems we used have
been successfully leveraged to model electrophysiological
and contractile alterations due to drugs or inherited muta-
tions (Blinova et al., 2018; Paik et al., 2020), their applica-
tion tomodelingCOVID-19 still requires further validation.s, respectively. Statistical analyses of intra-experimental variability
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Figure 6. Force Production of 3D-EHTs Made from hiPSC-CMs Progressively Declines during SARS-CoV-2 Infection
(A) Schematic representation of the magnetic sensing system: the 3D-EHT is suspended between two posts (one rigid, one flexible). The
magnet is localized inside the flexible post, and the post movement during 3D-EHT contraction is recorded by giant magnetoresistance
(GMR) sensor located at the bottom of the dish (converting displacement into voltage changes).
(B) Representative picture of a 3D-EHT. Scale bar, 1 mm.
(C) SARS-CoV-2 viral RNA and particles detected in 3D-EHTs infected at 10 MOI at specified time points. Intracellular viral RNA is plotted on
the right axis as percent HPRT1; extracellular viral particles are plotted on the right axis as PFU/mL. Mean ± SEM of two 3D-EHTs per
condition.
(D) Representative time course analysis of twitch force in 3D-EHTs from WTC11c hiPSC-CMs after SARS-CoV-2 infection at 10 MOI. Data are
shown as mean ± SEM for two mock controls and four infected 3D-EHTs.
(E) Representative twitch traces of 3D-EHT at 10 MOI at different time points.
(F and G) (F) Immunofluorescent images of 3D-EHTs sections at different time points. Scale bars, 20 mm. (G) qRT-PCR of sarcomeric genes
in 3D-EHTs infected with SARS-CoV-2 at 10 MOI. Mean ± SEM of two 3D-EHTs.Nevertheless, a recent report by Dolhnikoff et al. (2020)
identified coronaviral particles in the cytoplasm of cardio-
myocytes, endothelial cells, and fibroblasts by electron mi-
croscopy in the heart of an 11-year-old child who died from
multi-system inflammatory syndrome in children
following COVID-19 infection. This indicates that in vivo
cardiomyocytes with substantially greater maturity than
used here are susceptible to SARS-CoV-2 infection.
COVID-19 patients are commonly treated with steroids to
control systemic inflammation. However, our data suggest
that treatments aimed to control the direct damage of
SARS-CoV-2, not only by preventing infection but also by
preventing viral replication or rescuing cardiac function,
should also be taken into consideration to prevent long-
term cardiovascular complications.488 Stem Cell Reports j Vol. 16 j 478–492 j March 9, 2021EXPERIMENTAL PROCEDURES
Cell Culture
RUES2 hESCs and WTC11c hiPSCs were maintained and differen-
tiated using small-molecule modulators of theWNT pathway (Ber-
tero et al., 2019a). H7 hESCs were differentiated in suspension
culture format by collaborators at the Center for Applied Technol-
ogy Development at the City of Hope in California. H9 hESCswere
maintained and differentiated into lateral mesoderm- and neural
crest-derived SMCs as described previously (Bargehr et al., 2016;
Serrano et al., 2019). ACE2 KO clones were generated using
CRISPR-Cas9 ribonucleoprotein complexes (Synthego).
Gene Expression Analysis
Bulk RNA-seq datasets fromRUES2 hESC-CMs had been previously
generated and analyzed (Bertero et al., 2019a). BulkmRNA-seq data
from infected cardiomyocytes were generated by constructing
mRNA-seq libraries using the KAPA mRNA HyperPrep Kit (Kapa
Biosystems). Libraries were sequenced on an Illumina NovaSeq.
For single-cell RNA-seq analysis, a single-cell suspensionwas gener-
ated from RUES2 hESC-CMs and single-cell RNA-seq was per-
formed using the Chromium Next GEM Single Cell 30 Kit (10X
Genomics). For real-time qRT-PCR, RNA from infected cardiomyo-
cytes was harvested using TRIzol reagent. cDNAwas obtained with
M-MLV reverse transcriptase (Invitrogen), and qRT-PCR was per-
formedwith SYBR SelectMasterMix (Applied Biosystems). Primers
are reported in Table S5.
Western Blot
hPSC-CMs were lysed using RIPA Buffer. Samples were run on
mini-PROTEAN TGX precast gels (Bio-Rad) and then transferred
onto polyvinylidene fluoride membranes. Primary and secondary
antibodies (Supplemental Experimental Procedures) were incu-
bated in blocking buffer, and fluorescent signals were acquired us-
ing a GelDoc Imager (Bio-Rad).
SARS-CoV-2 Generation
All experiments using live virus were performed in the Biosafety
Level 3 (BSL-3) facility at the University of Washington in compli-
ance with the BSL-3 laboratory safety protocols (CDC BMBL 5th
ed.) and the recent CDC guidelines for handling SARS-CoV-2.
SARS-related coronavirus 2, Isolate USA-WA1/2020 (SARS-CoV-2)
and icSARS-CoV-2mNG were obtained from BEI Resources (NR-
52281) and the University of Texas (Xie et al., 2020), respectively,
and propagated in VERO cells (USAMRIID). Viral preparations and
culture supernatant from SARS-CoV-2-infected cardiomyocytes
were titered using a plaque assay.
Viral Infection
SARS-CoV-2 wild-type or expressing mNeonGreen protein was
diluted to the desired MOI in DMEM and incubated on hPSC-
CMs or hPSC-SMCs for 1 h at 37C (non-infected [mock] controls
were incubated with DMEM only). Cells were then washed with
Dulbecco’s Phosphate-buffered Saline (DPBS) and cultured in the
appropriate maintenance media.
Immunofluorescence
hPSC-CMs were fixed with 4% paraformaldehyde (PFA) and
permeabilized using 0.25% Triton X-100 (Sigma-Aldrich) before
staining with primary and secondary antibodies (Supplemental
Experimental Procedures).
Electron Microscopy
hPSC-CMs were fixed with Karnovsky’s fixative. Heavy metal
impregnation was performed as detailed elsewhere (Deerinck
et al., 2010). Thin sections were viewed using a JEOL 1230 trans-
mission electron microscope.
Electrophysiological Analysis with MEA
CytoView MEA plates (Axion BioSystems) were coated with Matri-
gel and hPSC-CMs were plated as described previously (Bertero
et al., 2019b). SARS-CoV-2 effects on hPSC-CMs electrophysiologywere recorded using the Maestro Pro system and analyzed with
Cardiac Analysis Software v.3.1.8 (all from Axion BioSystems).
3D-EHTs Analysis
Post-suspended, fibrin-based 3D-EHTs were generated with hPSC-
CMs and HS27a stromal cells (ATCC) at a 1:10 ratio. Twitch force
was recorded by tracking the movement of magnets embedded
in the flexible posts, as described previously (Bielawski et al.,
2016). For immunostaining, 3D-EHTs were arrested in diastole,
fixed in 4% PFA, and embedded in Tissue-Tek O.C.T. before
sectioning and staining.
Statistical Analyses
Statistical analyses were performed only for experiments with
more than two replicates using Prism 8.1.3 (GraphPad). The type
and number of replicates, the statistics plotted, the statistical test
used, and the test results are described in the figure legends.
Data and Code Availability
The data supporting this publication have been made available in
GEO under accession numbers: GSE157175 (single-cell RNA-seq)
and GSE162736 (bulk RNA-seq).
SUPPLEMENTAL INFORMATION
Supplemental Information can be found online at https://doi.org/
10.1016/j.stemcr.2021.02.008. More extensive descriptions of all
methods and reagents are included in the Supplemental Experi-
mental Procedures section.
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